Table 1 presents the cytokine levels in serum and CSF. Many studies have led to understanding more about MS pathology; because of this since the early 1990s, disease-modifying drugs have been introduced for the MS treatment. The standard treatment includes interferon-β (INF-β) and glatiramer acetate (GA); these are immunomodulator agents. INF-β inhibits proinflammatory cytokines (TNFα, IL-6, IL-1β, and IL-17) and T-cell proliferation and clinically reduces the annual rate of relapsing [64, 65]. This evidence concerns the gene IL1B and myeloid sarcoma.